Estimating life expectancy and related probabilities in screen-detected breast cancer patients with restricted follow-up information

Statistics in Medicine

Volumn 23, Issue 3, 2004, Pages 431-448

  Straatman, Huub ^a   Verbeek, André L M ^a   Peer, Petronella G M ^a   Borm, George ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Cancer screening; Estimating life expectancy; Lead time; Restricted follow up; Screen detected cancer patient; Survival

Indexed keywords

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SCREENING; CANCER SURVIVAL; CAUSE OF DEATH; EARLY DIAGNOSIS; FOLLOW UP; HEALTH PROGRAM; HUMAN; LIFE EXPECTANCY; LIFESPAN; MAXIMUM LIKELIHOOD METHOD; OUTCOMES RESEARCH; RISK REDUCTION; STATISTICAL DISTRIBUTION; STATISTICAL MODEL; SURVIVAL RATE; SURVIVAL TIME;

AGED; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIFE EXPECTANCY; MIDDLE AGED; MODELS, STATISTICAL; SURVIVAL ANALYSIS;

EID: 0842346676     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1539     Document Type: Article

References (23)

1. Shapiro S, Venet W, Strax P, Venet L, Roeser R. Ten-to fourteen-year effect of screening on breast cancer mortality. Journal of the National Cancer Institute 1982; 69:349-355.
2. Tabár L, Gad A, Holmberg LH, Ljungquist U, Eklund G, Fagerberg CJG, Baldetrop L, Grönthoft O, Lundström B, Månson JC, Day NE. Reduction in mortality from breast cancer after mass screening with mammography. Lancet 1985; i:829-832.
3. Frisell J, Glas U, Hellström L, Somell A. Randomised mammographic screening for breast cancer in Stockholm: design, first round results and comparison. Breast Cancer Research and Treatment 1986; 8:45-54.
4. Andersson I, Aspegren K, Janzon L, Landberg T, Lindholm K, Linell F, Ljungberg O, Ranstam J, Sigfússon B. Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial. British Medical Journal 1988; 297:943-948.
5. Tabár L, Fagerberg G, Duffy SW, Day NE. The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit. Journal of Epidemiology and Community Health 1989; 43:107-114.
6. Roberts MM, Alexander FE, Anderson TJ, Chetty U, Donnan PT, Forrest P, Hepburn W, Huggins A, Kirkpatrick AE, Lamb J, Muir BB, Prescott RJ. Edinburgh trial of screening for breast cancer: mortality at seven years. Lancet 1990; i:241-246.
7. Peer PGM, Verbeek ALM. Mass screening for breast cancer in women younger than 50 years; a literature review of the anticipated effect on mortality. Nederlands Tijdschrift voor Geneeskunde 1991; 135:651-655.
8. Kerlikowske K, Grady D, Rubin S, Sandrok C, Ernster V. Efficacy of screening mammography; a meta-analysis. Journal of the American Medical Association 1995; 273:149-154.
9. National Board of Health and Welfare. Mammography screening for early detection of breast cancer in Sweden. NBHW Series Publication No. 17, article No: 1998-03-017, ISBN 91-7201-299-4, Socialstyrelsen, Stockholm, Sweden (1998).
10. Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjöld B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002; 359:909-919.
11. Demissie K, Mills OF, Rhoads GG. Empirical comparison of the results of randomized controlled trials and case-control studies in evaluating the effectiveness of screening mammography. Journal of Clinical Epidemiology 1998; 51(2):81-91.
12. Walter SD, Stitt LW. Evaluating the survival of cancer cases detected by screening. Statistics in Medicine 1987; 6:885-900.
13. Habbema JDF, Van Oortmarssen GJ, Van Putten DJ. An analysis of survival differences between clinically and screen-detected cancer patients. Statistics in Medicine 1983; 2:279-285.
14. Aron JL, Prorok PC. An analysis of the mortality effect in a breast cancer screening study. International Journal of Epidemiology 1986; 15:36-43.
15. Kafadar K, Prorok PC. A data-analytic approach for estimating lead time and screening benefit based on survival curves in randomized cancer screening trials. Statistics in Medicine 1994; 13:569-586.
16. Xu JL, Prorok PC. Non-parametric estimation of the post-lead-time survival distribution of screen-detected cancer cases. Statistics in Medicine 1995; 14:2715-2725.
17. Clayton DG. Fitting a general family of failure-time distributions using GLIM. Applied Statistics 1983; 32:102-109.
18. Otten JDM, van Dijck JAAM, Peer PGM, Straatman H, Verbeek ALM, Mravunac M, Hendriks JHCL, Holland R. Long term breast cancer screening in Nijmegen, The Netherlands: the nine rounds from 1975-92. Journal of Epidemiology and Community Health 1996; 50:353-358.
19. Kopans DB. The breast cancer screening controversy and the National Institutes of Health Consensus Development Conference on breast cancer screening for women ages 40-49. Radiology 1999; 210:4-9.
20. Walter SD, Day NE. Estimation of the duration of a preclinical disease status using screening data. American Journal of Epidemiology 1983; 118:865-886.
21. Day NE, Walter SD. Simplified models of screening for chronic disease: estimation procedures for mass screening programs. Biometrics 1984; 40:36-43.
22. Duffy SW, Chen H, Tabár L, Day NE. Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry and exit from the preclinical detectable phase. Statistics in Medicine 1995; 14:1531-1543.
23. Straatman H, Peer PGM, Verbeek ALM. Estimating lead time and sensitivity in a screening program without estimating the incidence in the screened group. Biometrics 1997; 53:217-229.